OCTALFA is active and involved in supporting entrepreneurship in France. Its purpose is to promote academic and industrial research in the healthcare sector. Its missions are to identify inventions and expertises that will benefit to patients, coordinate research and feasibility studies prior to the inception of the company, define its strategy, set up the management and fund R&D until the market introduction of products or signing of structuring partnerships.

OCTALFA therefore supports companies until they achieve profitability, are sold or receive backing from an industrial or financial organisation.



We identify new projects, assess their
feasibility before implementing the strategy
and the economic model.


We validate the project with the inventor partners.


We fund companies created with a long-term vision.


We define strategy, then structure,
grow and manage companies created.


  • ORPHELIA Pharma

    SINCE 2015
    ORPHELIA Pharma is a pharmaceutical company dedicated to the development and marketing of pediatric drugs for oncology and CNS diseases.

  • Mathym

    INCEPTED IN 2013
    Nanotechnology company dedicated to the development, manufacturing and commercialization of innovative colloidal solutions

  • OREGA Biotech

    INCEPTED IN 2010
    Biotechnology company dedicated to the research and development of novel antibodies for cancer immunotherapy

  • Alizé Pharma 3

    SINCE 2014
    Biopharmaceutical company developing innovative peptides for the treatment of osteoporosis and certain bone diseases


    Millendo Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel treatments for endocrine diseases.


    SINCE 2007
    Clinical-stage biopharmaceutical company developing AZP-531, an analog of unacylated ghrelin for the treatment of Prader-Willi Syndrome and type 2 Diabetes. Acquired mainly by Millendo Therapeutics in 2017.

  • Nightswapping

    SINCE 2014
    Startup company developing novel collaborative tourism tools

  • JUVISE Pharmaceuticals

    FROM 2011 TO 2017
    Pharmaceutical company marketing products to treat psychiatric, inflammatory and respiratory diseases.


  • ORPHELIA Pharma has been awarded a €1m loan from Bpifrance
  • Interleukin-17 patent granted in Europe
  • Granting of the marketing authorization for Kigabeq®
  • Orphelia Pharma at Bio-Europe

    Gilles Alberici, chairman of Orphelia Pharma, will attend the 24th conference Bio-Europe in Copenhagen. Please meet on November 5 to 7.

  • CHMP has adopted a positive opinion for Kigabeq®, the first pediatric formulation of vigabatrin
  • Pierre Attali joins ORPHELIA Pharma Board Of Directors
  • Meet us at the following congresses in 2018

    Jeremy Bastid will attend the following H1-2018 congresses:

    ANR – Advances in Neuroblastoma Research
    San Francisco May 9 -12

    ASCO – American Society of Clinical Oncology
    Chicago June 1 – 5

    BIO International Convention – Boston June 4 – 7

  • ORPHELIA Pharma announces the filing of a European Marketing Authorization Application for Kigabeq®